Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/12/2018
SIETES contiene 92610 citas

 
 
 1 a 20 de 2193 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102844]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM, for the ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102843]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Ryan J, Radziszewska B, Grimm R, Murray AM, for the ASPREE Investigator Group. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102842]
4.Enlace a cita original Cita con resumen
Huang W-Y, Singer DE, Wu J-L, Chiang C-E, Weng H-H, Lee M, Ovbiagele B. Association of intracranial hemorrhage risk with non–vitamin K antagonist oral anticoagulant use vs aspirin use. A systematic review and meta-analysis. JAMA Neurology 2018:13 de agosto. [Ref.ID 102795]
5.Enlace a cita original Cita con resumen
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY, for the Clinical Research Collaboration Neurological Emergencies Treatment Trials Network and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:19 de julio. [Ref.ID 102746]
6.Enlace a cita original Cita con resumen
Rothwell PPM, Cook PNR, Gaziano PJM, Price JF, Belch PJFF, Roncaglioni MC, Morimoto T, Mehta Z. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018:12 de julio. [Ref.ID 102745]
7.Enlace a cita original Cita con resumen
Patel TK, Patel TB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:junio. [Ref.ID 102626]
8.Enlace a cita original Cita con resumen
Hart RG, Sharma M, Mundl H, Kasner SE, Bagdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonskowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ, NAVIGATE ESUS Investigators. Ribaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-201. [Ref.ID 102610]
9. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
10.Enlace a cita original Cita con resumen
Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]
11.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dekkers T, Lafeber M, Kramers C. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102523]
12.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wang X, Karnieg T. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102522]
13. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
14. Cita con resumen
Jull A, Wadham A, Bullen C, Parag V, Kerse N, Waters J. Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU). BMJ 2017;359:j5157. [Ref.ID 102158]
15. Cita con resumen
Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]
16.Tiene citas relacionadas Cita con resumen
Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med 2017;377:1580-2. [Ref.ID 102100]
17.Tiene citas relacionadas Cita con resumen
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, ten Berg JM, Steg PG, Hohnloser SH, for the RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-24. [Ref.ID 102099]
18. Cita con resumen
Ekelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Díaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim J-H, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Bruns NC, Misselwitz F, Chen E, Leong D, Yusuf S, for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017:5 de octubre. [Ref.ID 102087]
19.Tiene citas relacionadas Cita con resumen
Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59. [Ref.ID 102014]
20. Cita con resumen
Rojas-Velandia C, Ruiz-Garzón J, Moscoso-Alcina J-C, Vallejos-Narváez A, Castro-Canoa J, Bustos-Martínez Y, Flórez-Cutiva M, Contreras-Muñoz M, Gómez-Gil JC, Calderón-Ospina C-A. Characterization of adverse drug reactions causing admission to an intensive care unit. Br J Clin Pharmacol 2017;83:1134-40. [Ref.ID 101974]
Seleccionar todas
 
 1 a 20 de 2193 siguiente >>